Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study

Authors: Roussel, Murielle ^*, Lauwers-Cances, Valérie, Macro, Margaret, Leleu, Xavier, Royer, Bruno, Hulin, Cyrille, Karlin, Lionel, Perrot, Aurore, Touzeau, Cyrille, Chrétien, Marie-Lorraine, Rigaudeau, Sophie, Dib, Mamoun, Nicolas-Virelizier, Emmanuelle, Escoffre-Barbe, Martine, Belhadj, Karim, Mariette, Clara, Stoppa, Anne-Marie, Araujo, Carla, Doyen, Chantal, Fontan, Jean, Kolb, Brigitte, Garderet, Laurent, Brechignac, Sabine, Malfuson, Jean-Valère, Jaccard, Arnaud, Lenain, Pascal, Borel, Cécile, Hebraud, Benjamin, Benbrahim, Omar, Dorvaux, Véronique, Manier, Salomon, Augeul-Meunier, Karine, Vekemans, Marie-Christiane, Randriamalala, Edouard, Chaoui, Driss, Caers, Jo, Chaleteix, Carine, Benboubker, Lofti, Vincent, Laure, Glaisner, Sylvie, Zunic, Patricia, Slama, Borhane, Eveillard, Jean-Richard, Humbrecht-Kraut, Catherine, Morel, Véronique, Mineur, Philippe, Eisenmann, Jean-Claude, Demarquette, Hélène, Richez, Valentine, Vignon, Marguerite, Caillot, Denis, Facon, Thierry, Moreau, Philippe, Colin, Anne-Laurène, Olivier, Pascale, Wuilleme, Soraya, Avet-Loiseau, Hervé, Corre, Jill, Attal, Michel

Source: In Blood 5 May 2022 139(18):2747-2757

Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM.

Authors: Malard, Florent, Bobin, Arthur, Labopin, Myriam, Karlin, Lionel, Frenzel, Laurent, Roussel, Murielle, Vignon, Marguerite, Godet, Sophie, Chalopin, Thomas, Moyer, Perrine, Chalayer, Emilie, Orsini Piocelle, Frederique, Mariette, Clara, Croizier, Carolyne, Sohn, Claudine, Dib, Mamoun, Le Calloch, Ronan, Ali-Ammar, Nadia, Loirat, Marion, Benbrahim, Omar

Source: Blood Cancer Journal; 12/19/2024, Vol. 14 Issue 1, p1-4, 4p

Subject Terms: BISPECIFIC antibodies, CYTOKINE release syndrome, LOGISTIC regression analysis, TERMINATION of treatment, T cells

ZOHé: A Prospective Study of the Use of Biosimilar Filgrastim Zarzio in Clinical Practice in Patients Treated With Chemotherapy for Lymphoid Malignancies

Authors: Damaj, Gandhi Laurent, Benbrahim, Omar, Hacini, Maya, Voronina, Inna, Benabed, Khaled, Soumoudronga, Ravaka-Fatoma, Gasnereau, Isabelle, Haioun, Corinne, Solal-Céligny, Philippe

Source: In Clinical Lymphoma Myeloma and Leukemia June 2017 17(6):362-369

Real‐life effectiveness of carfilzomib in patients with relapsed multiple myeloma receiving treatment in the context of early access: The CARMYN study.

Authors: Laribi, Kamel, Leleu, Xavier, Texier, Nathalie, Germain, Raphaël, Touzeau, Cyrille, Hammoud, Mohammad, Payssot, Alexandre, Schulmann, Samantha, Le Calloch, Ronan, Trebouet, Adrien, Chaoui, Driss, David, Selva, Benbrahim, Omar, Benramdane, Riad, Charvet‐Rumpler, Anne, Jadeau, Christelle, Rouanet, Eglantine, Decaux, Olivier, Perrot, Aurore

Source: EJHaem; Feb2024, Vol. 5 Issue 1, p55-60, 6p

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation

Authors: Quinquenel, Anne ^*, Letestu, Rémi ^*, Le Garff-Tavernier, Magali ^*, Subtil, Fabien ^*, Aurran-Schleinitz, Therese ^*, Laribi, Kamel ^*, Cymbalista, Florence ^*, Levy, Vincent ^*, Simon, Laurence ^*, Roos-Weil, Damien ^*, Leblond, Véronique ^*, Dilhuydy, Marie-Sarah ^*, Dartigeas, Caroline ^*, Tomowiak, Cecile ^*, Guieze, Romain ^*, Tournilhac, Olivier ^*, Ferrant, Emmanuelle ^*, de Guibert, Sophie ^*, Feugier, Pierre ^*, Merabet, Fatiha ^*, Lepretre, Stephane ^*, Carassou, Philippe ^*, Gay, Julie ^*, Hivert, Bénédicte ^*, Fornecker, Luc Mathieu ^*, Dupuis, Jehan ^*, Molina, Lysiane ^*, Villemagne, Bruno ^*, Cartron, Guillaume ^*, Drenou, Bernard ^*, Mahé, Béatrice ^*, Benbrahim, Omar ^*, Cahu, Xavier ^*, Portois, Christelle ^*, Ysebaert, Loic ^*, Nguyen Khac, Florence ^*, Rouille, Valérie ^*, Delmer, Alain, Michallet, Anne-Sophie ^*

Source: In Blood 15 November 2022 140 Supplement 1:7007-7009

Dexaml-02 : A Phase II Study of Dexamethasone Added to Induction and Postremission Therapy in Older Patients with Newly Diagnosed AML. a French Innovative Leukemia Organization (FILO) Study

Authors: Recher, Christian, Bertoli, Sarah ^*, Peterlin, Pierre ^*, Guieze, Romain ^*, Desbrosses, Yohan ^*, Hicheri, Yosr ^*, Benbrahim, Omar ^*, Carre, Martin ^*, Mathilde, Hunault-Berger ^*, Banos, Anne ^*, Bernard, Marc ^*, Gyan, Emmanuel, Saad, Alain ^*, Chebrek, Safia ^*, Roth Guepin, Gabrielle ^*, Dorvaux, Veronique ^*, Sanhes, Laurence ^*, Gallego Hernanz, Maria Pilar ^*, Exbrayat, Carole ^*, Vincent, Laure ^*, Himberlin, Chantal ^*, Largeaud, Laetitia ^*, Delabesse, Eric ^*, Vergez, Francois ^*, Vey, Norbert, Mineur, Ariane C ^*, Simand, Célestine ^*, Luquet, Isabelle ^*, Pigneux, Arnaud ^*

Source: In Blood 15 November 2022 140 Supplement 1:6149-6151

The use of octagam and gammanorm in immunodeficiency associated with hematological malignancies: a prospective study from 21 French hematology departments.

Authors: Benbrahim, Omar¹ (AUTHOR) omar.benbrahim@chr-orleans.fr, Viallard, Jean-François² (AUTHOR), Choquet, Sylvain³ (AUTHOR), Royer, Bruno⁴ (AUTHOR), Bauduer, Frédéric⁵ (AUTHOR), Decaux, Olivier⁶ (AUTHOR), Crave, Jean-Charles⁷ (AUTHOR), Fardini, Yann⁸ (AUTHOR), Clerson, Pierre⁸ (AUTHOR), Lévy, Vincent⁹ (AUTHOR)

Source: Hematology. Dec2019, Vol. 24 Issue 1, p173-182. 10p.

Subject Terms: *HEMATOLOGIC malignancies, *CHRONIC lymphocytic leukemia, *HEMATOLOGY, *HODGKIN'S disease, *LONGITUDINAL method

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Interim Results of MRD Kinetics in the Eradic Trial from the Filo Group

Authors: Michallet, Anne-Sophie, Quinquenel, Anne, Letestu, Remi, Magali, Tavernier, Morisset, Stéphane, Aurran, Therese, Laribi, Kamel, Cymbalista, Florence, Levy, Vincent, Simon, Laurence, Roos Weil, Damien, Leblond, Veronique, Dilhuydy, Marie Sarah, Tomowiak, Cecile, Dartigeas, Caroline, Guieze, Romain, Tournilhac, Olivier, Ferrant, Emmanuelle, De Guibert, Sophie, Feugier, Pierre, Merabet, Fatiha, Lepretre, Stéphane, Carassou, Philippe, Gay, Julie, Hivert, Benedicte, Fornecker, Luc Matthieu, Dupuis, Jehan, Molina, Lysiane, Villemagne, Bruno, Cartron, Guillaume, Drenou, Bernard, Mahé, Béatrice, Benbrahim, Omar, Cahu, Xavier, Portois, Christelle, Ysebaert, Loic, Nguyen Khac, Florence, Rouillé, Valerie, Delmer, Alain Jacques

Source: In Blood 2 November 2023 142 Supplement 1:3268-3268

Prospective Follow-up of Patients with Myelofibrosis (MF) and Treated with Ruxolitinib in France: The Rumycup Study

Authors: Kiladjian, Jean-Jacques, Boyer perrard, Françoise ^*, Laribi, Kamel ^*, Ianotto, Jean-Christophe ^*, Ranta, Dana ^*, Benbrahim, Omar ^*, Bologna, Serge ^*, Cony-Makhoul, Pascale ^*, Santagostino, Alberto ^*, Zerazhi, Hacene ^*, Slimani, Abla ^*, Fitoussi, Olivier ^*, Etienne, Gabriel ^*

Source: In Blood 15 November 2022 140 Supplement 1:3968-3969

Retrospective Analysis of the Outcomes of Patients with Relapsed/Refractory Acute Myeloid Leukemia Included in a Patient Named Program of Gemtuzumab Ozogamicin

Authors: Lambert, Juliette, Peterlin, Pierre, Pautas, Cecile, Raffoux, Emmanuel, Caillot, Denis, Legrand, Ollivier, Joris, Magalie, Berceanu, Anna, Malfuson, Jean Valere, Chantepie, Sylvain, Bernard, Marc, Gastaud, Lauris, Pigneux, Arnaud, Benbrahim, Omar, Bonmati, Caroline, Mathilde, Hunault-Berger, Dombret, Hervé, Rousselot, Philippe, Chevret, Sylvie, Castaigne, Sylvie

Source: In Blood 23 November 2021 138 Supplement 1:876-876

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR

Authors: Michallet, Anne-Sophie, Quinquenel, Anne, Letestu, Remi, Le Garff-Tavernier, Magali, Subtil, Fabien, Elsensohn, Mad-Helenie, Aurran, Therese, Laribi, Kamel, Cymbalista, Florence, Levy, Vincent, Simon, Laurence, Roos-Weil, Damien, Leblond, Veronique, Dilhuydy, Marie-Sarah, Tomowiak, Cécile, Dartigeas, Caroline, Guieze, Romain, Tournilhac, Olivier, Ferrant, Emmanuelle, de Guibert, Sophie, Feugier, Pierre, Merabet, Fatiha, Leprêtre, Stéphane, Carassou, Philippe, Gay, Julie, Hivert, Bénédicte, Fornecker, Luc Mathieu, Dupuis, Jehan, Molina, Lysiane, Villemagne, Bruno, Cartron, Guillaume, Drenou, Bernard, Mahé, Béatrice, Benbrahim, Omar, Cahu, Xavier, Portois, Christelle, Ysebaert, Loic, Nguyen-Khac, Florence, Rouille, Valérie, Delmer, Alain

Source: In Blood 23 November 2021 138 Supplement 1:641-641

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

Relapsed or refractory chronic lymphocytic leukemia retreated with rituximab in daily practice: final results of the PERLE study.

Authors: Chaoui, Driss, Leprêtre, Stéphane, Liu, Kun Lun, Barry, Marly, Tempescul, Adrian, Dilhuydy, Marie-Sarah, Chaib, Abdelaziz, Slama, Borhane, Labourey, Jean Luc, Benbrahim, Omar, Dreyfus, Brigitte, Hacini, Maya, Mahé, Béatrice, Maynadié, Marc, Delmer, Alain, Benkanoun, Chahinez, Boissard, Frédéric, Gandon, Sophie, Veerabudun, Kalaivani, Choquet, Sylvain

Source: Leukemia & Lymphoma; Jun2019, Vol. 60 Issue 6, p1563-1567, 5p

Subject Terms: CHRONIC lymphocytic leukemia, PROGRESSION-free survival

Bortezomib and High-Dose Melphalan Vs. High-Dose Melphalan As Conditioning Regimen before Autologous Stem Cell Transplantation in De Novo Multiple Myeloma Patients: A Phase 3 Study of the Intergroupe Francophone Du Myelome (IFM 2014-02)

Authors: Roussel, Murielle ^*, Hebraud, Benjamin ^*, Lauwers-Cances, Valerie ^*, Macro, Margaret ^*, Leleu, Xavier, Hulin, Cyrille ^*, Karlin, Lionel ^*, Royer, Bruno ^*, Perrot, Aurore ^*, Moreau, Philippe ^*, Caillot, Denis ^*, Rigaudeau, Sophie ^*, Dib, Mamoun ^*, Nicolas-Virelizier, Emmanuelle ^*, Escoffre-Barbe, Martine ^*, Belhadj, Karim ^*, Pegourie, Brigitte ^*, Stoppa, Anne-Marie, Araujo, Carla ^*, Doyen, Chantal, Fontan, Jean ^*, Kolb, Brigitte ^*, Garderet, Laurent, Brechignac, Sabine ^*, Malfuson, Jean Valere ^*, Dorvaux, Veronique ^*, Lenain, Pascal ^*, Benbrahim, Omar ^*, Jaccard, Arnaud ^*, Borel, Cecile ^*, Avet Loiseau, Herve, Attal, Michel

Source: In Blood 8 December 2017 130 Supplement 1:398-398

Long Term Outcome of Patients with MPN-Associated Myelofibrosis Treated with Peg-Interferon-α2a, a French Intergroup of Myeloproliferative Neoplasms (FIM) Study

Authors: Ianotto, Jean-Christophe ^*, Chauveau, Aurélie ^*, Boyer-Perrard, Francoise ^*, Gyan, Emmanuel, Laribi, Kamel ^*, Cony-Makhoul, Pascale ^*, Demory, Jean-Loup ^*, De Renzis, Benoit ^*, Dosquet, Christine ^*, Rey, Jerome ^*, Roy, Lydia ^*, Dupriez, Brigitte, Knoops, Laurent ^*, Legros, Laurence ^*, Malou, Mohamed ^*, Hutin, Pascal ^*, Ranta, Dana ^*, Benbrahim, Omar ^*, Ugo, Valerie, Lippert, Eric ^*, Kiladjian, Jean-Jacques

Source: In Blood 8 December 2017 130 Supplement 1:323-323

Use of Human Immunoglobulins in Secondary Immunodeficiencies Associated with Hematological Malignancy in Real-Life Practice: Which Patients, Which Treatment?

Authors: Benbrahim, Omar ^*, Grosbois, Bernard, Viallard, Jean-François ^*, Choquet, Sylvain ^*, Royer, Bruno ^*, Dreyfus, Brigitte ^*, Fleck, Emmanuel ^*, Carreiro, Miguel ^*, Clerson, Pierre ^*, Crave, Jean Charles ^*, Delain, Jean-christophe ^*, Levy, Vincent ^*

Source: In Blood 6 December 2014 124(21):4972-4972

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.